

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
April 12, 2016

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren D. Tesh, PharmD, BCPS

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA
Silver Spring, Maryland

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Deborah K. Armstrong, MD

(Chairperson)

Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Bernard F. Cole, PhD

Professor
Department of Mathematics and Statistics
University of Vermont
Burlington, Vermont

Tito Fojo, MD, PhD

Professor of Medicine
Division of Medical Oncology
Department of Medicine
Columbia University
New York, New York

Michael E. Menefee, MD

Assistant Professor of Medicine
Mayo Clinic Jacksonville
Jacksonville, Florida

Grzegorz S. Nowakowski, MD

Assistant Professor of Medicine
Mayo Clinic Rochester
Rochester, Minnesota

Brian I. Rini, MD, FACP

Professor of Medicine
Cleveland Clinic Taussig Cancer Institute
Glickman Urological and Kidney Institute
Cleveland, Ohio

Bruce J. Roth, MD

Professor of Medicine
Division of Oncology
Washington University School of Medicine
St. Louis, Missouri

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 12, 2016

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

William Douglas Figg, Sr., PharmD, MBA

Senior Investigator and Head of the Clinical Pharmacology Program in the Office of the Clinical Director, Center for Cancer Research (CCR) National Cancer Institute (NCI) National Institutes of Health (NIH) Head of Molecular Pharmacology Section Deputy Branch Chief in the Genitourinary Malignancies Branch, CCR, NCI, NIH Bethesda, Maryland

Terry Gillespie

(Patient Representative)
Westmont, Illinois

Donald E. Mager, PharmD, PhD

Associate Professor of Pharmaceutical Sciences Department of Pharmaceutical Sciences University at Buffalo, State University of New York Buffalo, New York

Michele Orza, ScD

(Acting Consumer Representative)
Senior Advisor to the Executive Director Patient-Centered Outcomes Research Institute (PCORI) Washington, District of Columbia

Arun Rajan, MD

Associate Research Physician Thoracic and GI Oncology Branch CCR, NCI, NIH Bethesda, Maryland

Eva Szabo, MD

Chief Lung & Upper Aerodigestive Cancer Research Group Division of Cancer Prevention, NCI, NIH Bethesda, Maryland

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP

Executive Medical Director, Amgen Oncology Therapeutic Area Head, US Medical Organization Thousand Oaks, California

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 12, 2016

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director
Office of Hematology and Oncology Products
(OHOP)
Office of New Drugs (OND), CDER, FDA

Patricia Keegan, MD

Director
Division of Oncology Products 2 (DOP2)
OHOP, OND, CDER, FDA

Gideon Blumenthal, MD

Medical Team Leader
Thoracic/Head & Neck Cancer Team
DOP2, OHOP, OND, CDER, FDA

Lola Fashoyin-Aje, MD, MPH

Medical Officer
Thoracic/Head & Neck Cancer Team
DOP2, OHOP, OND, CDER, FDA

Chao Liu, PhD

Pharmacometrics Reviewer
Division of Pharmacometrics (DPM)
Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS)
CDER, FDA